OnKure Therapeutics (OKUR) director Liam Ratcliffe granted 22,350 stock options
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. reported that director Liam Ratcliffe received a grant of 22,350 stock options, each representing the right to buy one share of Class A Common Stock at an exercise price of $4.14 per share. All 22,350 options will vest on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Ratcliffe holds 22,350 derivative securities of this option award, which is scheduled to expire on August 6, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ratcliffe Liam
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 22,350 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 22,350 shares (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
Key Figures
Options granted: 22,350 options
Exercise price: $4.14 per share
Expiration date: August 6, 2036
+3 more
6 metrics
Options granted
22,350 options
Stock Option (right to buy) granted to director Liam Ratcliffe
Exercise price
$4.14 per share
Conversion or exercise price for the 22,350 stock options
Expiration date
August 6, 2036
Scheduled expiration of the granted stock options
Underlying shares
22,350 shares
Class A Common Stock underlying the option award
Post-transaction holdings
22,350 derivative securities
Total options held in this award after the transaction
Vesting date trigger
June 4, 2027
100% vesting on earlier of this date or day prior to next annual meeting
Key Terms
Stock Option (right to buy), exercise price, vesting, Class A Common Stock
4 terms
Stock Option (right to buy) financial
"security_title is listed as Stock Option (right to buy)"
exercise price financial
"conversion or exercise price is stated as 4.1400 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares subject to the option will vest on the earlier of June 4, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Class A Common Stock financial
"underlying security title is identified as Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
What did OnKure Therapeutics (OKUR) director Liam Ratcliffe receive in this Form 4?
Director Liam Ratcliffe received a grant of 22,350 stock options to purchase Class A Common Stock at an exercise price of $4.14 per share, expiring on August 6, 2036, subject to vesting conditions.
What is the vesting schedule for Liam Ratcliffe’s new OKUR stock options?
All 22,350 options will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual stockholder meeting, conditioned on Ratcliffe continuing as a service provider through the vesting date.
What is the exercise price of the stock options granted to Liam Ratcliffe at OnKure Therapeutics (OKUR)?
The granted stock options have an exercise price of $4.14 per share for 22,350 underlying shares of Class A Common Stock, as disclosed in the Form 4 derivative transaction details.
How many OnKure Therapeutics (OKUR) options does Liam Ratcliffe hold after this transaction?
Following this award, Liam Ratcliffe’s reported holding for this option grant is 22,350 derivative securities, each for one share of Class A Common Stock, all held as direct ownership according to the Form 4.
When do Liam Ratcliffe’s OnKure Therapeutics (OKUR) options expire?
The stock options granted to Liam Ratcliffe are scheduled to expire on August 6, 2036. They become exercisable after vesting, which occurs in full on the specified earlier vesting date condition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
